1. Давыдов М.И., Полоцкий Б.Е. Рак легкого - М: Радикс, 1994, 206 стр.
2. Трахтенберг А.Х., Чиссов В.И. Клиническая онколопульмонология - М.,
3. The Health Consequences of Smoking: A Report of the Surgeon General (ed 2010/07/30). Atlanta (GA): U.S. Department of Health and Human Services. Centers for Disease Controland Prevention (US) 2004
4. Goldstraw P. Staging Manual in Thoracic Oncology. An International Association for the Study of Lung Cancer Publication, 2009.
5. Fossella FV, Putnam JB, Komaki R., eds. Lung Cancer. M.D.AndersenCancer Care Serires. New York: Springer; 2003: 316
6. Schrump DS, Carter D, KelseyCR, et al. Non-small cell lung cancer. In DeVita Jr. VT, LawrenceTS, Rosenberg SA, et al., eds. DeVita, Hellman, and Rosenberg Cancer; Prinsiples and Practice of Oncology. Philadelphia; Lippincott Williams and Wilkins; 2011
7. Аллахвердиев А.К., Давыдов М.М. Торакоскопическая лобэктомия с медиастинальной лимфодиссекцией стандарт в хирургическом лечении больных немелкоклеточным раком легкого T1-2N0M0 // Вопр. онкол. 2015 -Т. 61, N3, стр. 413-417
8. Gopaldas R.R., Bakaeen F.G., Dao T.K. et al. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13619 patients // Ann. Thorac. Surg. -2010. - Vol. 89, N 5. - P. 1563-1570
9. Higuchi M., Yaginuma H., Yonechi A. et al. Long-term outcomes after videoassisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage Ia non-small cell lung cancer // J. Cardiothorac. Surg. - 2014. - Vol. 9. - P. 88-92
10. Naruke T. Lymph node metastasis of lung cancer and associated surgery // Asian Medical Journal, 1990, v. 33, N 12, h. 668-677.
11. Paul S., Altorki N.K., Sheng S. et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS Database // J. Thorac. Cardiovasc. Surg. - 2010 - Vol. 139. - P. 366-378
12. Scott W.J., Allen M.S., Darling G. et al. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Sugeons Oncology Group Z0030 randomised clinical trial // J. Thorac. Cardiovasc. Surg. - 2010. - Vol. 139. - P. 976-981.
13. Ginsberg R.J., Rubinstein L.V. Randomised trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer // Ann. Thorac. Surg. - 1995. - Vol. 60. - P.615-622
14. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med 2004; 350: 351-360/
15. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med 2005; 352: 2589-2597
16. Douillard J.Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-smallcell lung cancer (ANITA): a randomized controlled trial. Lancet Oncol.2006: 7: 719-727.
17. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperativw cisplatin and gemcitabine in stages IB to IIIA non-small-celllung cancer. J.Clin. Oncol. 2012; 30: 172-178.
18. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small-cell lung cancer randomized phase III trial RTOG 9410. J. Natl. Cancer Inst 2011; 103: 1452-1460.
19. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV NonSmall0Cell Lung Cancer. American Society of Clinical Oncology. Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3488-3515
20. Burroto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small-cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400-410
21. Sequst LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol ; 2013: 31:3327-3334.
22. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015
23. Solomon BJ, Mok T, Kim DW et al. First-line crisotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med 2013 ; 371: 2167-2177
24. Costa DB, Shaw AT, Ou SH et al. Clinical Experience With Crisotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin. Oncol. 2015; 33:1881-1888
25 Camidge DR, Bang YU, Kwak EL , et al Activity and safety of crisotinib in patients with ALK-positive non-small-cell lung cancer, updated results from a phase 1 study Lancet Oncol 2012; 13: 1011-1019
26 Shaw AT, Yeap BY, Solomon BJ et al Impact of crisotinib on survival in patients with advanced , ALK-positive NSCLC compared with historical controls [abstract] J Clin Oncol 2011; 29 (Suppl 15): Abstract 7507
27 Scagliotti GV, Parikh P, von Pawel J et al Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer J Clin Oncol 2008; 26:3543- 3551
28 D Addario G, Pintile M, Leighi NB, et al Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer : a meta-analysis of published literature J Clin Oncol 2005; 23:2926-2936
29 :Sandler A, Yi J, Dahlberg S, et al Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599of bevacisumab with paclitaxel/carboplatin for advanced non-small-cell lung cancer J Thorac Oncol 2010; 5:1416-1423
30 Azzoli cG, Temin S, Aliff T, et al 2011 Focused Update of 2009American Society of Clinical Oncology Clinical Practice Guideline Update of Chemotherapy for Stage IV Non-Small-Cell Lung Cancer J Clin Oncol 2011; 29: 3825-3831